Oral semaglutide: the innovation in type 2 diabetes management
Oral semaglutide is the first-in-class glucagon-like peptide-1 receptor agonist available in the form of pills administered per os. PIONEER — the clinical trial program assessing the efficacy and safety of oral semaglutide — demonstrated the dose-dependent efficacy of the drug: the reduction of up...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | article |
| Langue: | EN RU |
| Publié: |
Endocrinology Research Centre
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/99990b0602704bc38e17bcf6dfbda6fa |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|